A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)

  • Kwan, Edmond (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/MonH/530
NMA SSA Reference Number: SSA/17/MonH/630
Monash Health Ref: RES-17-0000-634A
Effective start/end date2/10/181/10/23


  • clinical trial
  • prostate cancer
  • treatment efficacy